Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
2004 1
2005 4
2006 2
2007 1
2008 1
2009 6
2010 4
2011 12
2012 20
2013 17
2014 17
2015 16
2016 11
2017 29
2018 24
2019 18
2020 43
2021 47
2022 47
2023 45
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

327 results

Results by year

Filters applied: . Clear all
Page 1
The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.
Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, Amoura Z, Andrade D, Andreoli L, Artim-Esen B, Atsumi T, Avcin T, Belmont HM, Bertolaccini ML, Branch DW, Carvalheiras G, Casini A, Cervera R, Cohen H, Costedoat-Chalumeau N, Crowther M, de Jesus G, Delluc A, Desai S, De Sancho M, Devreese KM, Diz-Kucukkaya R, Duarte-Garcia A, Frances C, Garcia D, Gris JC, Jordan N, Leaf RK, Kello N, Knight JS, Laskin C, Lee AI, Legault K, Levine SR, Levy RA, Limper M, Lockshin MD, Mayer-Pickel K, Musial J, Meroni PL, Orsolini G, Ortel TL, Pengo V, Petri M, Pons-Estel G, Gomez-Puerta JA, Raimboug Q, Roubey R, Sanna G, Seshan SV, Sciascia S, Tektonidou MG, Tincani A, Wahl D, Willis R, Yelnik C, Zuily C, Guillemin F, Costenbader K, Erkan D; ACR/EULAR APS Classification Criteria Collaborators. Barbhaiya M, et al. Among authors: sciascia s. Arthritis Rheumatol. 2023 Oct;75(10):1687-1702. doi: 10.1002/art.42624. Epub 2023 Aug 28. Arthritis Rheumatol. 2023. PMID: 37635643
2023 ACR/EULAR antiphospholipid syndrome classification criteria.
Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, Amoura Z, Andrade D, Andreoli L, Artim-Esen B, Atsumi T, Avcin T, Belmont HM, Bertolaccini ML, Branch DW, Carvalheiras G, Casini A, Cervera R, Cohen H, Costedoat-Chalumeau N, Crowther M, de Jesús G, Delluc A, Desai S, Sancho M, Devreese KM, Diz-Kucukkaya R, Duarte-García A, Frances C, Garcia D, Gris JC, Jordan N, Leaf RK, Kello N, Knight JS, Laskin C, Lee AI, Legault K, Levine SR, Levy RA, Limper M, Lockshin MD, Mayer-Pickel K, Musial J, Meroni PL, Orsolini G, Ortel TL, Pengo V, Petri M, Pons-Estel G, Gomez-Puerta JA, Raimboug Q, Roubey R, Sanna G, Seshan SV, Sciascia S, Tektonidou MG, Tincani A, Wahl D, Willis R, Yelnik C, Zuily C, Guillemin F, Costenbader K, Erkan D; ACR/EULAR APS Classification Criteria Collaborators. Barbhaiya M, et al. Among authors: sciascia s. Ann Rheum Dis. 2023 Oct;82(10):1258-1270. doi: 10.1136/ard-2023-224609. Epub 2023 Aug 28. Ann Rheum Dis. 2023. PMID: 37640450
Antiphospholipid syndrome.
Schreiber K, Sciascia S, de Groot PG, Devreese K, Jacobsen S, Ruiz-Irastorza G, Salmon JE, Shoenfeld Y, Shovman O, Hunt BJ. Schreiber K, et al. Among authors: sciascia s. Nat Rev Dis Primers. 2018 Jan 11;4:17103. doi: 10.1038/nrdp.2017.103. Nat Rev Dis Primers. 2018. PMID: 29321641 Review.
Daratumumab monotherapy for refractory lupus nephritis.
Roccatello D, Fenoglio R, Caniggia I, Kamgaing J, Naretto C, Cecchi I, Rubini E, Rossi D, De Simone E, Del Vecchio G, Cozzi M, Sciascia S. Roccatello D, et al. Among authors: sciascia s. Nat Med. 2023 Aug;29(8):2041-2047. doi: 10.1038/s41591-023-02479-1. Epub 2023 Aug 10. Nat Med. 2023. PMID: 37563241 Free PMC article.
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, Boumpas DT, Brodin N, Bruce IN, González-Gay MÁ, Jacobsen S, Kerekes G, Marchiori F, Mukhtyar C, Ramos-Casals M, Sattar N, Schreiber K, Sciascia S, Svenungsson E, Szekanecz Z, Tausche AK, Tyndall A, van Halm V, Voskuyl A, Macfarlane GJ, Ward MM, Nurmohamed MT, Tektonidou MG. Drosos GC, et al. Among authors: sciascia s. Ann Rheum Dis. 2022 Jun;81(6):768-779. doi: 10.1136/annrheumdis-2021-221733. Epub 2022 Feb 2. Ann Rheum Dis. 2022. PMID: 35110331
Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study.
Bettiol A, Urban ML, Bello F, Fiori D, Mattioli I, Lopalco G, Iannone F, Egan A, Dagna L, Caminati M, Negrini S, Bargagli E, Folci M, Franceschini F, Padoan R, Flossmann O, Solans R, Schroeder J, André M, Moi L, Parronchi P, Roccatello D, Sciascia S, Jayne D, Prisco D, Vaglio A, Emmi G; European EGPA Study Group. Bettiol A, et al. Among authors: sciascia s. Ann Rheum Dis. 2022 Dec;81(12):1769-1772. doi: 10.1136/ard-2022-222776. Epub 2022 Jul 18. Ann Rheum Dis. 2022. PMID: 35850947 No abstract available.
Antiphospholipid syndrome.
Khamashta M, Taraborelli M, Sciascia S, Tincani A. Khamashta M, et al. Among authors: sciascia s. Best Pract Res Clin Rheumatol. 2016 Feb;30(1):133-48. doi: 10.1016/j.berh.2016.04.002. Epub 2016 May 4. Best Pract Res Clin Rheumatol. 2016. PMID: 27421221 Free article. Review.
Immunological Rare Diseases.
Baldovino S, Menegatti E, Roccatello D, Sciascia S. Baldovino S, et al. Among authors: sciascia s. Adv Exp Med Biol. 2017;1031:497-509. doi: 10.1007/978-3-319-67144-4_26. Adv Exp Med Biol. 2017. PMID: 29214588 Review.
327 results